Trial Profile
A phase II study of Gemzar [gemcitabine], Novantrone [mitoxantrone] and Rituxan [rituximab] in relapsed or refractory mantle cell lymphoma (MCL) (B9E-US-X436).
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Gemcitabine (Primary) ; Mitoxantrone (Primary) ; Rituximab (Primary)
- Indications Mantle-cell lymphoma
- Focus Therapeutic Use
- 05 May 2008 New trial record.